Showing Results for: “Glycemic Index and Diabetes”

Strategic collaboration formed to raise awareness that all people with diabetes on blood glucose-lowering medications should have glucagon, preferable a ready-to-use formulation The American Diabetes Association ® (ADA) and Xeris Pharmaceuticals ® (Xeris BioPharma Holdings, Inc.), a national supporter of the ADA, are pleased to announce a multi-year strategic partnership to reinforce the importance of prescribing glucagon, preferably ready-to-use, for all individuals with diabetes who are treated with insulin and/or insulin secretagogues or those at high risk of hypoglycemia (low blood glucose

Findings highlight potential to expand oral GLP-1 RA treatment options for patients with type 2 diabetes and obesity Findings from two phase 2 studies demonstrated positive outcomes for elecoglipron, an investigational oral, once-daily, small molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA), in patients with type 2 diabetes and obesity with weight-related comorbidities. The studies showed reductions in body weight, improvements in A1C (a key measure of average blood glucose levels) and cardiometabolic measures along with a favorable safety profile. Researchers presented data from

New Study Highlights the Importance of Early Glycemic Screening in High-Risk Children to Prevent Long-Term Health Complications from Diabetes New research from the National Institutes of Health (NIH) found that blood glucose levels obtained at childhood examinations predicted future diabetes related complications such as kidney disease (nephropathy) and eye disease (retinopathy). The findings were presented at the American Diabetes Association® (ADA) 2023 Scientific Sessions in San Diego, CA and were simultaneously published in the Diabetes Care journal. This data comes at a time when the

SGLT2i Shown as Potential Solution to Help Manage Renal Complications and Improve Glycemic Control for Young Individuals Living with Type 1 Diabetes Today, findings from the ATTEMPT study, showed that a low-dose of SGLT2 inhibitor could safely be given to youth and adolescents with type 1 diabetes to improve kidney function and glycemic management. ATTEMPT is the first of its kind, landmark trial designed to evaluate the effectiveness of SGLT2 inhibitors to optimize diabetes control and prevent early subclinical kidney complications in an at-risk pediatric population with type 1 diabetes. The

In a comparison of two different diet and two different weight management programs, results of the international PREVIEW intervention study found a low, similar rate of progression to type 2 diabetes (T2D) among people with prediabetes who had initially lost weight on a low-calorie diet (LCD), according to a symposium presentation today titled “PREVIEW Study Results—Prevention of Diabetes through Lifestyle Intervention and Population Studies Around the World” at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions® in San Francisco. The study showed no difference between

Phase 2 Study Results Highlight Use of Once-Daily Injection for Weight Loss and Reduction in Insulin Use A new study evaluating the role of acmopatide (CT-868), a once-daily dual glucagon-like peptide 1/gastric inhibitory polypeptide receptor agonist (GLP-1/GIP RA) injection, found that treatment improved blood glucose management, reduced body weight, and was generally well tolerated in patients with type 1 diabetes. The phase 2 trial results were presented today as a symposium at the 2026 Scientific Sessions of the American Diabetes Association ® in New Orleans. Approximately 1.2 million

Findings Reveal Efficacy of Novel Inhaler to Improve Glycemic Control for Patients with Type 1 Diabetes Today, findings from INHALE-3, a pivotal trial examining the use of inhaled insulin in adults with type 1 diabetes (T1D), were announced, highlighting the potential of an alternative insulin solution to enhance diabetes management. The results were presented as a symposium at the 84th Scientific Sessions of the American Diabetes Association® (ADA) in Orlando, FL. Diabetes affects 11.6% of the American population and millions of individuals globally, type 1 diabetes requires ongoing insulin

People with type 2 diabetes should be considered in remission after sustaining normal blood glucose (sugar) levels for three months or more, according to a new consensus statement from the American Diabetes Association ® (ADA), the Endocrine Society, the European Association for the Study of Diabetes and Diabetes UK jointly published in Diabetes Care, the J ournal of Clinical Endocrinology & Metabolism, Diabetologia, and Diabetic Medicine, respectively. About 10% of the U.S. population has diabetes, and these numbers continue to rise. People with type 2 diabetes can achieve “remission” by

Learn how to read carbs on a label, count total carbohydrates, and understand nutrition claims like fat-free, low sodium, and high fiber. Decode labels to make informed food choices for better health.

Novel Drugs Demonstrate Benefits of Once Weekly Drugs for Weight Loss and Glycemic and Blood Pressure Control Findings from three studies showcase new data on the latest developments in drug therapy innovations to treat obesity including new insights on GLP-1 (Glucagon-like peptide-1) receptor agonists. The data was presented as a late-breaking poster and oral presentations, respectively at the American Diabetes Association® (ADA) 84th Scientific Sessions in Orlando, FL. The studies are part of a host of research and development driven by interest in new GLP-1 drugs and concerns about obesity